Business Context and Reporting Period
This Form 8-K is a current report filed by MediciNova, Inc. on November 30, 2010. The filing discloses the termination of a material definitive agreement effective on the report date.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the terminated agreement:
- Consulting Fee Rate: $27,500 per month under the terminated agreement with Danerius, LLC.
Material Changes
MediciNova terminated the consulting agreement dated June 12, 2009 (as amended September 23, 2009) with Danerius, LLC, an affiliate of Director Alan W. Dunton, M.D. The agreement, which provided consulting services for product development programs, was originally scheduled to expire on October 12, 2011. Dr. Dunton remains a member of the Board of Directors following the termination.
Outlook, Risks, and Contingencies
Following the termination, Danerius, LLC remains subject to obligations regarding MediciNova's confidential and proprietary information. The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of other risks and contingencies.
Investor Verification Points
- Confirm the cessation of the $27,500 monthly consulting expense effective November 30, 2010.
- Verify that Dr. Alan W. Dunton retains his position on the Board of Directors despite the termination of the affiliate's consulting contract.
- Review subsequent filings for any new agreements related to product development previously covered by the terminated contract.